Skip to main content
SpringerLink
Log in

The evidence-based use of induction chemotherapy in Breast Cancer

Breast Cancer volume 8, pages 23–37 (2001)Cite this article

Abstract

The use of induction chemotherapy, also known as pre-operative or neoadjuvant chemotherapy has been studied in a number of randomised trials. Response rates are generally high, ranging from 70-90%, which allows for the downstaging of primary tumours and breast conservation surgery. Conserving surgery as opposed to mastectomy in this setting appears to be safe, effective and improves quality of life, although there is a suggestion of a small increase in local recurrence rate. Data from the randomised trials presented in this review shows that the use of induction chemotherapy neither prolongs nor decreases overall or disease free survival when compared with the same chemotherapy given in an adjuvant setting. There is a direct correlation between response of a primary breast tumour to induction chemotherapy and patient outcome, probably because this approximates the effect of induction chemotherapy on micrometastases which are present at presentation in many patients with apparently localised primary breast cancers. A pathological complete response after surgery is an excellent predictor of long term outcome, and is more likely to be seen in smaller tumours. Induction chemotherapy can be used as anin vivo measure of tumour response to treatment. This allows a further option of switching cytotoxic drugs in apparently resistant tumours.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Mansi JL, Gogas H, Bliss JM,et al: Outcome of primary-breast-patients with micrometastases: a long-term follow-up study.Lancet 354:197–202, 1999.

    Article  PubMed  CAS  Google Scholar 

  2. Redding WH, Coombes RC, Monoghan P,et al: Detection of isolated mammary carcinoma cells in patients with primary breast cancer.Lancet ii:1271–1273, 1983.

    Google Scholar 

  3. Cote RJ, Rosen PP, Lesser ML,et al: Prediction of early relapse in patients with operable breast cancer by detection of occult bone micrometastases.J Clin Oncol 9:1749–1756, 1991.

    PubMed  CAS  Google Scholar 

  4. Mansi JL, Berger U, Easton D,et al: Micrometastases in bone marrow in patients with primary breast cancer: evaluation as an early predictor of bone metastases.BMJ 295:1093–1096, 1987.

    Article  PubMed  CAS  Google Scholar 

  5. Braun S, Pantel K, Muller P,et al: Cytokeratin-Positive Cells In The Bone Marrow And Survival of Patients With Stage I, II, Or III Breast Cancer.NEJM 342:525–533, 2000.

    Article  PubMed  CAS  Google Scholar 

  6. Mamounas EP: Overview of National Surgical Adjuvant Breast Project neoadjuvant chemotherapy studies.Semin Oncol 25:31–35, 1988.

    Google Scholar 

  7. Schwartz GF, Birchansky CA, Komarnicky LT,et al: Induction chemotherapy followed by breast conservation for locally advanced carcinoma of the breast.Cancer 73:362–369, 1994.

    Article  PubMed  CAS  Google Scholar 

  8. Early Breast Cancer Trialists’ Collabarative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 33 randomised trials involving 33,000 recurrences and 24,000 deaths among 75,000 women.Lancet 339:1–15, 71-85, 1992.

    Google Scholar 

  9. Forrest AP, Levack PA, Chetty U,et al: A human tumour model.Lancet 2:840–842, 1986.

    Article  PubMed  CAS  Google Scholar 

  10. Stephens FO: The case for a name change from neoadjuvant chemotherapy to induction chemotherapy.Cancer 63:1245–1246, 1989.

    Article  PubMed  CAS  Google Scholar 

  11. Halstead WS: The results of operations for the cure of cancer of the breast performed at The Johns Hopkins Hospital from June, 1889 to January.Johns Hopkins Hosp Rep 1894-1895 4:297–350, 1894.

    Google Scholar 

  12. Leroy d’Etoilles JJJ: Une lettre de M. Leroy d’Etoilles sur l’extirpation des tumeurs cancereuses.Bull Acad Med 9:454–458, 1867.

    Google Scholar 

  13. Paget J: Statistiek van den kanker (Cancer statistics).Ned Weekl Geneesk 2:275, 410, 1852.

    Google Scholar 

  14. Christian MC, McCabe MS, Korn EL,et al: The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06.N Eng J Med 333:1469–1474, 1995.

    Article  CAS  Google Scholar 

  15. Treatment of early-stage breast cancer. JAMA 265:391–395, 1991.

  16. AG, Hoffman RG, Howell-Pelz A,et al: Effect of Nancy Reagan’s mastectomy on choice of surgery for breast cancer by US women.JAMA 279:762–766, 1998.

    Article  Google Scholar 

  17. Tasmuth T, von Smitten K, Kaslo E: Pain and other symptoms during the first year after radical and conservative surgery for breast cancer.Br J Cancer 74:2024–2031, 1996.

    PubMed  CAS  Google Scholar 

  18. Hack TF, Cohen L, Katz J,et al: Physical and phsychological morbidity after axillary lymph node dissection for breast cancer.J Clin Oncol 17:143–149, 1999.

    PubMed  CAS  Google Scholar 

  19. Haagensen CD, Stout AP: Carcinoma of the breast. II. Criteria of inoperability.Ann Surg 118:859–568, 1943.

    Article  PubMed  CAS  Google Scholar 

  20. Bonadonna G, De Lena M, Brombilla C,et al: Combination chemotherapy and combined modality in disseminated and locally advanced breast cancer. In: Montague ACV, Stonesifer GL, Lewinson EF eds, Breast cancer, progress in clinical and biological research. New York: Alan Liss, pp437–458, 1977.

    Google Scholar 

  21. Rubens RD, Armitage P, Winter PJ,et al: Prognosis in inoperable stage III carcinoma of the breast.Eur J Cancer 13:805–811, 1977.

    PubMed  CAS  Google Scholar 

  22. Chesshire PJ: The effect of multiple tumours on mammary tumour growth rates in the C3H mouse.Br J Cancer 24:542–527, 1970.

    Google Scholar 

  23. Gunduz N, Fisher B, Saffer EA: Effect of surgical removal on the growth and kinetics of residual tumor.Cancer Res 39:3861–3865, 1979.

    PubMed  CAS  Google Scholar 

  24. Fisher B, Gunduz N, Coyle J,et al: Presence of a growth-stimulating factor in serum following primary tumor removal in mice.Cancer Res 49:1996–2001, 1989.

    PubMed  CAS  Google Scholar 

  25. Fisher B, Saffer EA, Ruddock C,et al: Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice.Cancer Res 49:2002–2004, 1989.

    PubMed  CAS  Google Scholar 

  26. Goldie JH, Coldman AJ: A mathematical model fo relating drug sensitivity of tumors to their spontaneous mutation rate.Cancer Treatment Rep 63:1727–1733, 1979.

    CAS  Google Scholar 

  27. Fidler IJ, Ellis LM: The implications for angiogenesis for the biology and therapy of cancer metastasis.Cell 79:185–188, 1996.

    Article  Google Scholar 

  28. Skipper HE, Schabel FM: Quantitative and cytokinetic studies in experimental tumor models. In: Holland JF, Frei E eds, Cancer Medicine, PA Lea and Febiger, Philadelphia, pp629–650, 1973.

    Google Scholar 

  29. Budman DR, Berry DA, Cirrincione CT: Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer.JNCI 90:1205–1211, 1998.

    Article  PubMed  CAS  Google Scholar 

  30. Fisher B, Bauer M, Wickerham DL,et al: Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer: An NSABP update.Cancer 52:1551, 1983.

    Article  PubMed  CAS  Google Scholar 

  31. Clark GM: Do we really need prognostic factors for breast cancer.Breast Cancer Res Treat 30:117, 1994.

    Article  PubMed  CAS  Google Scholar 

  32. Fisher B, Rockette H, Robidoux A,et al: Effect of pre-operative therapy for breast cancer (BC) on local-regional disease: First report of NSABP B-18.Proc Am Soc Clin Oncol 13:64 (abstr 57), 1994.

    Google Scholar 

  33. Mamounas E, Fisher B, Rockette H,et al: Clinical and pathologic local-regional response of operable breast cancer (BC) to preoperative chemotherapy. Results from NSABP-B18. Society of Surgical Oncology meeting, March 20–24, 1996, Atlanta, GA.

  34. Fisher B, Brown A, Mamounas E,et al: Effect of pre-operative therapy for primary breast cancer (BC) on local-regional disease, disease-free survival (DFS) and survival (S). Results from NSABP-B18.Proc Am Soc Clin Oncol 16:127a (abstr 449), 1997.

    Google Scholar 

  35. Powles TJ, Hickish TF, Makris A,et al: Randomised trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer.J Clin Oncol 13:547–452, 1995.

    PubMed  CAS  Google Scholar 

  36. McCready DR, Hortobagyi GN, Kau SW,et al: The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer.Arch Surg 124:21–25, 1989.

    PubMed  CAS  Google Scholar 

  37. Ackland SP, Bitran JD, Dowlatshahi K: Management of locally advanced and inflammatory carcinoma of the breast.Surg Gynecol Obstet 161:399–408, 1985.

    PubMed  CAS  Google Scholar 

  38. Freeman HP, Wasfie TJ:Cancer of the breast in poor black women. Cancer 63:2562, 1989.

    Article  PubMed  CAS  Google Scholar 

  39. Stebbing J: Too much life on earth.QJM 90:597–579, 1997.

    Article  PubMed  CAS  Google Scholar 

  40. Scholl SM, Fourquet A, Asselain B,et al: Neo-adju-vant versus adjuvant chemotherapy in premenopausal patients with tumors too large for breast conserving surgery: Preliminary results of a randomised trial.Eur J Cancer 30A:645–652, 1994.

    Article  PubMed  CAS  Google Scholar 

  41. Semiglzov VF, Topuzov EE, Bavli JL,et al: Primary (neoadjuvant) chemotherapy and radiotherapy compared with primary radiotherapy alone in stage Ilb- IIIa breast cancer.Ann Oncol 5:591–595, 1994.

    Google Scholar 

  42. Mauriac L, Durand M, Avril A,et al: Effects of primary chemotherapy in conservative treatment of breast cancer patients with operable tumours larger than 3cm.Ann Oncol 2:347–354, 1991.

    PubMed  CAS  Google Scholar 

  43. Fisher B, Brown A, Mamounas E: Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18.J Clin Oncol 15:2483–2493, 1997.

    PubMed  CAS  Google Scholar 

  44. Fisher B, Mamounas EP: Preoperative chemothera- py: A model for studying the biology and therapy of primary breast cancer.J Clin Oncol 13:537–540, 1995.

    PubMed  CAS  Google Scholar 

  45. Fisher B, Ore L: On the underutilisation of breast- conserving surgery for the treatment of breast cancer.Ann Oncol 4:96–98, 1993.

    PubMed  CAS  Google Scholar 

  46. Fisher B, Bryant J, Wolmark N,et al: Effect of preoperative chemotherapy on the outcome of women with operable breast cancer.J Clin Oncol 16:2672–2685, 1998.

    PubMed  CAS  Google Scholar 

  47. Makris A, Powles TJ, Ashley SE,et al: A reduction in requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in primary breast cancer.Ann Oncol 9:1179–1184, 1998.

    Article  PubMed  CAS  Google Scholar 

  48. Recht A, Come SE, Henderson JE,et al: The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer.N Eng J Med 334:1356–1361, 1996.

    Article  CAS  Google Scholar 

  49. Hartsell WF, Recine DC, Griem KL,et al: Delaying the initiation of intact breast irradiation for patients with lymph node positive breast cancer increases the risk of local recurrence.Cancer 76:2497–2503, 1995.

    Article  PubMed  CAS  Google Scholar 

  50. Ellis P, Smith IE, Ashley S,et al: Clinical prognostic and predictive factors for predictive chemotherapy in operable breast cancer.J Clin Oncol 16:107–114, 1998.

    PubMed  CAS  Google Scholar 

  51. Mauriac L, MacGrogan G, Avril A,et al: Neoadjuvant chemotherapy for operable breast carcinoma larger than 3cm: A unicentre randomised trial with a 124- month median follow-up.Annals Oncol 10:47–52, 1999.

    Article  CAS  Google Scholar 

  52. Scholl SM, Asselain B, Beuzeboc P,et al: Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumors considered too large for breast conserving surgery. An update.Proc Annu Meet Am Soc Clin Oncol (abstr) 14:A200, 1995.

    Google Scholar 

  53. Fisher B, Wolmark N, Bauer M,et al: The accuracy of clinical nodal staging and of limited axillary dissec- tion as a determinant of histological nodal status in carcinoma of the breast.Surg Gynecol Obstet 152:765–772, 1981.

    PubMed  CAS  Google Scholar 

  54. McMasters KM, Hunt KK Neoadjuvant chemotherapy, locally advanced breast cancer, and quality of life.J Clin Oncol 17:441–444.

  55. Peoples GE, Regan Q, Heaton KM,et al: Breast conservation therapy for large primary and locally advanced breast cancers after induction chemotherapy.Ann Surg Oncol 1999 (in press).

  56. Bonadonna G, Valagussa P, Zucali R,et al: Primary chemotherapy in surgically resectable breast cancer.CA Cancer J Clin 45:227–243, 1995.

    Article  PubMed  CAS  Google Scholar 

  57. Verrill MW, Ashley SE, Walsh GA,et al: Pathological complete response (pCR) in patients treated with neoadjuvant chemotherapy for operable breast cancer.Breast Cancer Res Treat 50:328, 1998.

    Google Scholar 

  58. Eremin O, Walker LG, Smith IC,et al: Chemotherapy in breast cancer: Enhanced response with docetaxel. Presented at the 22nd Annual Breast Cancer Symposium, San Antonio, Texas 1999.

  59. Fernando IN, Powell TJ, Dowsett M,et al: Determin- ing factors which predict response to primary med- ical therapy in breast cancer using a single needle aspirate with immunocytochemical staining and flow cytometry.Virchows Archiv 426:155–161, 1995.

    Article  PubMed  CAS  Google Scholar 

  60. Ellis PA, Smith IE, Burton SA,et al: Changes in proliferation, apoptosis, and Bcl–2 in breast cancer specimens following neoadjuvant chemotherapy.Breast Cancer Res Treat 37:36, 1995.

    Google Scholar 

  61. Ellis PA, Smith IE, McCarthy K,et al: Preoperative chemotherapy induces apoptosis in early breast cancer.Lancet 349:849, 1997.

    Article  PubMed  CAS  Google Scholar 

  62. Archer CD, Ellis PA, Dowsett M,et al: C-erb-B2 positivity correlates with poor apoptotic response to chemotherapy in primary breast cancer.Breast Cancer Res Treat 50:237, 1998.

    Google Scholar 

  63. Johnston SRD, Boeddinghaus IM, Riddler S,et al: Idoxifene antagonises oestradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.Cancer Res 1999 (Submitted for publication).

  64. Makris A, Powles TJ, Dowsett M,et al: Prediction of response to neoadjuvant therapy in primary breast carcinomas.Clin Cancer Res 3:593–600, 1997.

    PubMed  CAS  Google Scholar 

  65. Chang J, Powles TJ, Allred DC,et al: Predictive molecular markers for clinical outcome following primary chemotherapy for operable breast cancer.Proc Am Soc Clin Oncol 17:384, 1998.

    Google Scholar 

  66. Makris A, Powles TJ, Ashley SE,et al: A reduction in the requirements for mastectomy in a randomised trial of neoadjuvant chemoendocrine therapy in primary breast cancer.Ann Oncol 9:1179–1184, 1998.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Specialist Registrar in Medical Oncology, The Royal Marsden Hospital, UK

    Justin Stebbing

  2. Specialist Registrar in Clinical Oncology, The Royal Postgraduate Medical School, The Hammersmith Hospital, UK

    Andrew Gaya

Authors
  1. Justin Stebbing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andrew Gaya
    View author publications

    You can also search for this author in PubMed Google Scholar

About this article

Cite this article

Stebbing, J., Gaya, A. The evidence-based use of induction chemotherapy in Breast Cancer. Breast Cancer 8, 23–37 (2001). https://doi.org/10.1007/BF02967475

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02967475

Key words

search

Navigation